|
||
Articles |

,
,
Institute of Molecular Biology, Academia Sinica, Nankang, Taipei 11529, Taiwan; and the
Graduate Institute of Microbiology, National Taiwan University School of Medicine, Taipei 10018, Taiwan
| Abstract |
|---|
|
|
|---|
Key Words: mitogen-activated protein kinase kinase Fas-associated death domain protein Fas FLIP apoptosis
Abbreviations used: DR, death receptor; FADD, Fas-associated death domain protein; FLICE, FADD-like ICE; FLIP, FLICE-inhibitory protein; ICE, IL-1β–converting enzyme; MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; nt, nucleotide(s); PI, propidium iodide; RT, reverse transcription.
Fas (APO-1, CD95) is a 45-kD transmembrane protein (1) which transmits apoptotic signals upon engagement by Fas ligand or by specific anti-Fas antibodies. The death pathway initiated from Fas involves a series of death- induced molecules (1). Fas-associated death domain protein (FADD; MORT1)1 is directly recruited to Fas upon Fas engagement (2, 3). FADD then binds caspase-8 (FADD-like IL-1β–converting enzyme [FLICE] or MACH; references 4–6), followed by eventual activation of caspase-3 (CPP32 [7, 8]). FADD is also recruited to TNFR1 by TNFR1-associated death domain protein (TRADD) adapter, and transmits the death signal downstream of TNF binding (9). More recently, FADD was identified as the common mediator for apoptosis triggered by death receptor (DR)3 and DR5 (10–14). In addition, FADD is essential for embryo development (14, 15).
Fas-initiated apoptosis is regulated by a few molecules, including Bcl-2, Bcl-XL, crmA, and inhibitor of apoptosis protein (IAP) (1). Of these regulatory molecules, one that interferes most upstream in the Fas-mediated death cascade is FLIP (FLAME-1, I-FLICE, CASH, casper), a homologue of FLICE (16–20). Both the short form and long form of FLIP (FLIPS and FLIPL) interact with FADD and FLICE. Overexpression of FLIP suppresses Fas- and TNF-induced apoptosis (16–18, 20). Increased expression of FLIP is found in Fas ligand–resistant melanoma cell lines and in melanoma tumors (16). A viral homologue of FLIP also prevents DR-induced apoptosis (21).
Fas-induced apoptosis in T lymphocytes is known to be antagonized by activation through TCRs (22–24). In search of an activation signal that interferes with Fas-triggered apoptosis, we identified mitogen-activated protein kinase (MAPK) as the major kinase pathway which inhibits FADD-mediated cell death. We also demonstrated that MAPK kinase (MKK) abrogated Fas-initiated apoptosis through the induction of FLIP expression. Our results reveal the molecular mechanism by which activation of MAPK, mostly through tyrosine kinase receptors and G protein–coupled receptors, attenuates apoptotic signals initiated by DRs in normal and transformed cells.
Plasmids.
Quantitation of FLIP mRNA.
Transfection, Immunoblot, and MAPK Assay.
Cell Death Measurement.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Reagents and Cell Lines.
TPA, A23187, and Con A were purchased from Sigma Chemical Co. (St. Louis, MO). PD 098059, SB 203580, wortmannin, rapamycin, and calphostin c were purchased from Calbiochem Corp. (San Diego, CA). Cyclosporin A was a gift of Sandoz Pharmaceutical Co. (Taipei, Taiwan). Anti– human Fas antibody CH-11 (25) was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti–mouse Fas antibody Jo2 was obtained from PharMingen (San Diego, CA). Human T cell leukemia Jurkat cells (TIB 152) were obtained from the American Type Culture Collection (Rockville, MD). Thymocytes and splenocytes were isolated from 8-wk-old MRL +/+ and MRL lpr/lpr mice (The Jackson Laboratory, Bar Harbor, ME). Splenic T cells were purified as described previously (26) and activated with TPA/A23187 for 24 h. Activated splenic T cells were then washed, and incubated in the presence of IL-2 (10 U/ml) for another 3 d before anti-Fas treatment. For stimulation of splenic T cells with Con A, glutaraldehyde-fixed B cells TA3 (27) were added as presenting cells.
pcDNA3-AU1-FADD (2) and caspase-3 (CPP32/ Yama [28]) were gifts of Dr. Vishva Dixit (University of Michigan, Ann Arbor, MI). The constitutively active form of MKK1, pMCL-MKK1-N3/S218E/S222D (29), was a gift of Dr. Natalie G. Ahn (University of Colorado, Boulder, CO). The active mutant of MKK3b [MKK3b(Glu189, Glu193); 30] was a gift of Dr. Jiahuai Han (Scripps Research Institute, La Jolla, CA). The full length of FLIP long form (–74 to +1515 nucleotides [nt]) was isolated by reverse-transcription (RT)-PCR, blunt ended, partially sequenced, and subcloned into the EcoRV site of pcDNA3 (Invitrogen Corp., Leek, The Netherlands) with an HA tag. FLIP antisense construct contained the antisense sequence of FLIP –74 to +615 nt in pcDNA3. Green fluorescence protein expression vector pGreen Lantern-1 was purchased from GIBCO BRL (Gaithersburg, MD).
2 µg of total RNA was used for cDNA synthesis by using oligo-dT as primer (31). 1/10 of the cDNA synthesized was then amplified by using the following primers: human (h)FLIPL/S 5', TGT TGC TAT AGA TGT GG; hFLIPL/S 3', CAG GTC TAT TCT GTG GA; hFLIPL 5', ACT ATG TGG TGT CAG AGG GCC AG; hFLIPL 3' is the same as hFLIPL/S 3'; murine (m)FLIP 5', GTC ACA TGA CAT AAC CCA GAT TGT; and mFLIP 3', GTA CAG ACT GCT CTC CCA AGC.
Jurkat T cells and activated splenic T cells were transfected with the DEAE-dextran method (32). For 293T cells, transfection was performed using the calcium phosphate method. Immunoblot was performed according to the method described previously (32). MAPK activity was analyzed by immunoprecipitation of cell lysate with anti-ERK2 C-14 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and the kinase activity of the immune complex was determined as described previously (26).
All cultures were performed in RPMI with 10% FCS (GIBCO BRL), 10 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 x 10–5 M 2-ME. The extent of apoptosis was determined by propidium iodide (PI) staining. At the indicated times after treatment with different agents, cells were harvested, washed twice in PBS, and resuspended in hypotonic fluorochrome solution (50 µg/ml PI, 0.1% sodium citrate, 0.1% Triton X-100 [33]). Cells were placed at 4°C in the dark overnight, and DNA content was analyzed by FACScan® (Becton Dickinson, Mountain View, CA). The fraction of cells with sub-G1 DNA content was assessed using the CellFit program (Becton Dickinson). For cells transiently transfected with FADD/MKK1, survival was monitored with cotransfection of green fluorescence protein expression vector pGreen Lantern-1 (GIBCO BRL [34]). Treated cells were examined using a fluorescence microscope (Nikon Inc., Melville, NY).
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
Inhibition of Fas-mediated Apoptosis in Jurkat T Cells by Con A Activation Was Mediated by MKK.
Anti-Fas antibody CH-11 (25) induced extensive cell death in Jurkat cells (Fig. 1 A). Activation of Jurkat cells by Con A reduced Fas-activated cell death from 75 to 20% (Fig. 1 A). The suppression of cell death was not due to activation-induced secretion of IL-2, as IL-2 (50 U/ml) by itself did not prevent Fas-activated apoptosis (not shown). The inhibition of Fas-triggered apoptosis must be due to the activation signal downstream of TCR engagement. We tested several signaling pathways that may be involved in the antagonism of Fas-induced cell death by using specific inhibitors for each pathway. The addition of PD 098059, a selective inhibitor of MKK (35), effectively abrogated the preventive effect of Con A (Fig. 1 A). Only a weak or minimal reversal effect was observed from inhibition of other signaling molecules on Con A–activated Jurkat T cells. The inhibitors tested included calphostin c, cyclosporin A, SB 203580, wortmannin, and rapamycin. Protein kinase C, phosphatidylinositide 3-kinase, and protein kinase B have been implicated to protect against Fas-mediated apoptosis (36, 37), yet MKK was the major kinase activated by Con A stimulation that antagonized Fas-initiated cell death. A role of MAPK in the suppression of Fas-induced T cell death by lectin has also been recently reported (23). The antiapoptotic activity of MKK was further confirmed by transient expression of active MKK1 (29) in Jurkat cells. Transfection of the vector alone (pcDNA3) did not interfere with Fas-induced apoptosis. The induction of MAPK (see below) by MKK1 prevented apoptosis of Jurkat cells triggered by anti-Fas antibody (Fig. 1 B). In contrast, the expression of active MKK3b (30), which led to activation of p38 MAPK (Fig. 1 C), did not increase resistance to Fas-induced apoptosis in Jurkat cells. Neither MKK1 nor MKK3b alone induces cell death of Jurkat cells (Fig. 1 B).
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Recent studies indicate that apoptotic signal transmitted by Fas engagement is enhanced by TCR signals in T hybridomas and in mature T cells (41, 42). Similarly, we have observed that anti-CD3 alone failed to protect Fas-induced apoptosis of activated splenic T cells (not shown). Our observation that Con A activation led to inhibition of Fas-initiated cell death in T cells (Figs. 1, 4, and 5) suggests that costimulation signals are required for effective antagonism of FADD-mediated apoptosis. This is consistent with a report on the protection against Fas-induced apoptosis by superantigen and CD28 in mature human T cells (24).
FADD is the apoptotic mediator of several DRs, including Fas, TNFR1, DR3, and DR5 (2, 3, 9–14). Hence, FADD is activated by death signals through the binding of the Fas ligand, TNF, and TNF-related apoptosis–inducing ligand (TRAIL), whereas MAPK is activated by engagement of tyrosine kinase receptor, G protein–coupled receptor, and protooncogenes (43, 44). The activation of MAPK is essential for cell proliferation and mitogenesis, yet its role in antiapoptosis is less definite. MAPK has been shown to inhibit apoptosis induced by nerve growth factor deprivation in PC12 cells (45). MAPK has also been demonstrated to be involved in the inhibition of ceramide-induced apoptosis by sphingosine 1-phosphate (46) and in the suppression of cardiac myocyte apoptosis by cardiotrophin 1 (47). Because of the diverse biological targets of MAPK, the mechanism of MAPK in the antagonism of apoptosis remains mostly elusive. This study reveals a novel mechanism by which MAPK antagonizes FADD-mediated death through the induction of a FADD inhibitor. Therefore, the antagonism of FADD-initiated apoptosis by MKK represents an interesting cross-talk between two distinct signaling pathways, one apoptotic and the other mitogenic. Given the range of physiological functions and pathological consequences mediated by DRs, the antagonism of FADD by MKK illustrates how the early stage of DR-induced apoptosis can be interrupted. Interestingly, the Fas-activated apoptotic process is accompanied by an early cleavage of Raf-1, the activator of MKK (48). In this manner, the antiapoptotic MKK pathway is inhibited during the progression of the death pathway. Further molecular characterization of the antagonism between FADD and MKK will help efforts to place DR-mediated apoptosis under the appropriate control.
| Acknowledgments |
|---|
Submitted: 30 April 1998
Revised: 26 July 1998
| References |
|---|
|
|
|---|
1 Nagata S. Apoptosis by death factor, Cell, 1997, 88, 355–365.[Medline]
2 Chinnaiyan AM, O'Rourke K, Tewari M & Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis, Cell, 1995, 81, 505–512.[Medline]
3 Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH & Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain, J Biol Chem, 1995, 270, 7795–7798.
4 Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R et al.. Flice, a novel FADD-homologue ICE/ CED-3-like protease, is recruited to the CD95(Fas/APO-1) death-inducing signaling complex, Cell, 1996, 85, 817–827.[Medline]
5 Boldin MP, Goncharov TM, Goltsev YV & Wallach D. Involvement of MACH, a novel MORT1/ FADD-interacting protease in Fas/APO-1- and TNF receptor-induced cell death, Cell, 1996, 85, 803–815.[Medline]
6 Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH & Peter ME. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC), EMBO J, 1997, 16, 2794–2804.[Medline]
7 Enari M, Talanian RV, Wong WW & Nagata S. Sequential activation of ICE-like and CPP32-like protease during Fas-mediated apoptosis, Nature, 1996, 380, 723–726.[Medline]
8 Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K & Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream process in Fas-induced apoptosis, J Exp Med, 1998, 187, 587–600.
9 Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME & Dixit VM. FADD/MORT1 is a common mediator of CD95 (Fas/Apo-1) and tumor necrosis factor-induced apoptosis, J Biol Chem, 1996, 271, 4961–4965.
10 Chinnaiyan AM, O'Rourke K, Yu G-L, Lyons RH, Garg M, Duan DR, Xing L, Gentz R, Ni J & Dixit VM. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95, Science, 1996, 274, 990–992.
11 Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA et al.. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL, EMBO J, 1997, 16, 5386–5397.[Medline]
12 Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J & Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-
B pathway, Immunity, 1997, 7, 821–830.[Medline]
13 Schneider P, Thome M, Burns K, Bodmer J-L, Hofmann K, Kataoka T, Holler N & Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-
B, Immunity, 1997, 7, 831–836.[Medline]
14 Yeh W-C, de la Pompa JL, McCurrach ME, Shu H-B, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K et al.. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis, Science, 1998, 279, 1954–1958.
15 Zhang J, Cado D, Chen A, Kabra NH & Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1, Nature, 1998, 392, 296–300.[Medline]
16 Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J-L, Schroter M, Burns K, Mattmann C et al.. Inhibition of death receptor signals by cellular FLIP, Nature, 1997, 388, 190–195.[Medline]
17 Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM & Wallach D. CASH, a novel caspase homologue with death effector domains, J Biol Chem, 1997, 272, 19641–19644.
18 Hu S, Vincenz C, Ni J, Gentz R & Dixit VM. I-FLICE, a novel inhibitor tumor necrosis factor receptor-1 and CD-95-induced apoptosis, J Biol Chem, 1997, 272, 17255–17257.
19 Shu H-B, Halpin DR & Goeddel DV. Casper is a FADD- and caspase-related inducer of apoptosis, Immunity, 1997, 6, 751–763.[Medline]
20 Srinivasula SM, Ahmad M, Ottlie S, Bullrich F, Banks S, Wang Y, Fernandes-Alnemri T, Croce CM, Litwack G, Tomaselli KJ et al.. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis, J Biol Chem, 1997, 272, 18542–18545.
21 Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer J-L, Schroter M et al.. Viral FLICE-inhibitory proteins (FLIPS) prevent apoptosis induced by death receptor, Nature, 1997, 386, 517–521.[Medline]
22 Klas C, Debatin K-M, Jonker RR & Krammer PH. Activation interferes with APO-1 pathway in mature human T cells, Int Immunol, 1993, 6, 625–630.
23 Holmstrom TH, Chow SC, Elo I, Coffey ET, Orrenius S, Sistonen L & Eriksson JE. Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling, J Immunol, 1998, 160, 2626–2636.
24 McLeod JD, Walker LSK, Patel YI, Boulougouris G & Sansom DM. Activation of human T cells with superantigen (staphylococcal enterotoxin B) and CD28 confers resistance to apoptosis via CD95, J Immunol, 1998, 160, 2072–2079.
25 Yonehara S, Ishii A & Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with receptor of tumor necrosis factor, J Exp Med, 1989, 169, 1747–1756.
26 Hsueh Y-P & Lai M-Z. JNK but not MAP kinase is sensitive to cAMP in T lymphocytes, J Biol Chem, 1995, 270, 18094–18098.
27 Lee M-R, Liou M-L, Liou M-L, Yang Y-F & Lai M-Z. cAMP analogs prevent activation-induced apoptosis of T cell hybridoma, J Immunol, 1993, 151, 5208–5217.[Abstract]
28 Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS & Dixit VM. Yama/CPP32β, a mammalian homolog of CED-3, is a crmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase, Cell, 1995, 81, 801–809.[Medline]
29 Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande GF, Woude & Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase, Science, 1994, 265, 966–970.
30 Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S & Han J. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β), J Biol Chem, 1996, 271, 17920–17926.
31 Lai M-Z, Jang Y-J, Chen L-K & Gefter ML. Restricted V-(D)-J junctional regions in the T cell response to
repressor: identification of residues critical for antigen recognition, J Immunol, 1990, 144, 4851–4856.[Abstract]
32 Hsueh Y-P, Liang H-E, Ng S-Y & Lai M-Z. CD28 costimulation activates CREB in T lymphocytes, J Immunol, 1997, 158, 85–93.[Abstract]
33 Nicoletti I, Migliorati G, Pagliacci MC, Grignani F & Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry, J Immunol Methods, 1991, 139, 271–279.[Medline]
34 Hsu S-C, Wu C-C, Luh T-Y, Chou C-K, Han S-H & Lai M-Z. Apoptotic signal of Fas is not mediated by ceramide, Blood, 1998, 91, 2658–2663.
35 Alessi DR, Cuenda A, Cohen P, Dudley DT & Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J Biol Chem, 1995, 270, 27489–27494.
36 del Carmen Ruiz-Ruiz, M., M. Izquierdo, G. de Murcia, and A. Lopez-Rivas. Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis, Eur J Immunol, 1997, 27, 1442–1450.[Medline]
37 Hauser P, Papoff G, Eramo A, Reif K, Cantrell DA & Ruberti G. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B, Eur J Immunol, 1998, 28, 57–69.[Medline]
38 Nishimura Y, Ishii A, Kobayashi Y, Yamasaki Y & Yonehara S. Expression and function of mouse Fas antigen on immature and mature T cells, J Immunol, 1995, 154, 4395–4403.[Abstract]
39 Hitoshi Y, Lorens J, Kitada S, Fisher J, LaBarge M, Ring HZ, Francke U, Reed JC, Kinoshita S & Nolan GP. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells, Immunity, 1998, 8, 461–471.[Medline]
40 Rafaeli Y, Parijs LV, London CA, Tschopp J & Abbas AK. Biochemical mechanism of IL-2 regulated Fas-mediated T cell apoptosis, Immunity, 1998, 8, 615–623.[Medline]
41 Wong B, Arron J & Choi Y. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis, J Exp Med, 1997, 186, 1939–1944.
42 Hornung F, Zheng L & Lenardo MJ. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes, J Immunol, 1997, 159, 3816–3822.[Abstract]
43 Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK, Proc Natl Acad Sci USA, 1993, 90, 5889–5892.
44 Cobb MH & Goldsmith EJ. How MAP kinases are regulated, J Biol Chem, 1995, 270, 14843–14846.
45 Xia Z, Dickens M, Raingeaud J, Davis RJ & Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinase on apoptosis, Science, 1995, 270, 1326–1331.
46 Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS & Spiegel S. Suppression of ceramide-mediated cell death by sphingosine-1-phosphate, Nature, 1996, 381, 800–803.[Medline]
47 Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH & Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy, J Biol Chem, 1997, 272, 5783–5791.
48 Widmann C, Gibson S & Johnson GL. Caspase-dependent cleavage of signaling protein during apoptosis, J Biol Chem, 1998, 273, 7141–7147.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|